

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination CURIEL ET AL.	
		10/697,535	Examiner	Art Unit
Scott D. Priebe, Ph.D.		1633	Page 1 of 1	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-6,824,771 B2	11-2004	Curiel et al.	424/93.2
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 00/67576 A1	11-2000	WIPO	Curiel et al.	---
	O	WO 01/23004 A1	04-2001	WIPO	Molnar-Kimber et al.	---
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)	
U	Imler et al., "Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors," Gene Ther. 3: 75-84, 1996	
V	Takayama et al. "VEGF promoter-based conditionally replicative adenovirus are useful for the treatment of lung cancer," Mol. Ther. 7(5, Part 2): S420, abstract 1089.	
W	Curiel, D.T., "Strategies to improve the therapeutic utility of conditionally replicative adenoviruses (CRAds) for cancer therapy," Proc. Amer. Assoc. Cancer Res. Ann. Meet. 43: 662-663, abstract 3287, March 2002	
X		

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.